CA2724592A1 - Agent d~induction/d~entretien de remission - Google Patents

Agent d~induction/d~entretien de remission Download PDF

Info

Publication number
CA2724592A1
CA2724592A1 CA2724592A CA2724592A CA2724592A1 CA 2724592 A1 CA2724592 A1 CA 2724592A1 CA 2724592 A CA2724592 A CA 2724592A CA 2724592 A CA2724592 A CA 2724592A CA 2724592 A1 CA2724592 A1 CA 2724592A1
Authority
CA
Canada
Prior art keywords
group
agent
day
remission
mtx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2724592A
Other languages
English (en)
Inventor
Kazuhiko Kuriyama
Tomoyuki KAGO
Tokutaro YASUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of CA2724592A1 publication Critical patent/CA2724592A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2724592A 2008-05-20 2009-05-19 Agent d~induction/d~entretien de remission Abandoned CA2724592A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008131634 2008-05-20
JP2008-131634 2008-05-20
PCT/JP2009/059176 WO2009142195A1 (fr) 2008-05-20 2009-05-19 Agent d’induction/d’entretien de rémission

Publications (1)

Publication Number Publication Date
CA2724592A1 true CA2724592A1 (fr) 2009-11-26

Family

ID=41340128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724592A Abandoned CA2724592A1 (fr) 2008-05-20 2009-05-19 Agent d~induction/d~entretien de remission

Country Status (19)

Country Link
US (1) US20110152275A1 (fr)
EP (1) EP2305305A4 (fr)
JP (1) JPWO2009142195A1 (fr)
KR (1) KR20110010638A (fr)
CN (1) CN102123735A (fr)
AU (1) AU2009250509A1 (fr)
BR (1) BRPI0908638A2 (fr)
CA (1) CA2724592A1 (fr)
CO (1) CO6280501A2 (fr)
IL (1) IL209441A0 (fr)
MA (1) MA32593B1 (fr)
MX (1) MX2010012676A (fr)
MY (1) MY154685A (fr)
NZ (1) NZ589412A (fr)
RU (1) RU2505288C2 (fr)
SG (1) SG191598A1 (fr)
TW (1) TW201000109A (fr)
WO (1) WO2009142195A1 (fr)
ZA (1) ZA201008340B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (fr) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
JP4571497B2 (ja) 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
EP1575576A2 (fr) * 2002-09-24 2005-09-21 Novartis AG Composes organiques
BRPI0407658A (pt) * 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
WO2005044780A1 (fr) * 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Derive d'acide aminocarboxylique, son sel d'addition et agent de regulation du recepteur s1p
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
WO2006041015A1 (fr) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. Dérivé d’aminoalcool, sel d’addition dudit dérivé, et agent immunosuppresseur
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
ES2529724T3 (es) * 2005-09-09 2015-02-25 Novartis Ag Tratamiento de enfermedades autoinmunes
PL1932522T3 (pl) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
JP2007169194A (ja) * 2005-12-21 2007-07-05 Kyorin Pharmaceut Co Ltd ジオキサフォスフォリナン誘導体とその付加塩及びスフィンゴシン−１−リン酸（ｓ１ｐ１，ｓ１ｐ４）受容体作動薬
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2659598A1 (fr) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Derive d'ester de l'acide aminophosphorique et modulateur durecepteur s1p contenant ledit derive en tant que principe actif
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
EP2109364A4 (fr) * 2006-12-15 2010-04-14 Abbott Lab Composés d'oxadiazole innovants
WO2008099781A1 (fr) * 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique ou prophylactique pour une maladie démyélinisante comprenant un dérivé d'amino alcool comme ingrédient actif
JP2008231027A (ja) * 2007-03-20 2008-10-02 Kyorin Pharmaceut Co Ltd アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
JP2008239546A (ja) * 2007-03-27 2008-10-09 Kyorin Pharmaceut Co Ltd アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤

Also Published As

Publication number Publication date
RU2010147292A (ru) 2012-06-27
MY154685A (en) 2015-07-15
IL209441A0 (en) 2011-01-31
NZ589412A (en) 2012-11-30
BRPI0908638A2 (pt) 2015-10-06
EP2305305A1 (fr) 2011-04-06
KR20110010638A (ko) 2011-02-01
JPWO2009142195A1 (ja) 2011-09-29
CN102123735A (zh) 2011-07-13
SG191598A1 (en) 2013-07-31
ZA201008340B (en) 2011-08-31
MX2010012676A (es) 2011-05-10
RU2505288C2 (ru) 2014-01-27
AU2009250509A8 (en) 2011-05-12
EP2305305A4 (fr) 2013-02-13
WO2009142195A1 (fr) 2009-11-26
MA32593B1 (fr) 2011-09-01
TW201000109A (en) 2010-01-01
US20110152275A1 (en) 2011-06-23
AU2009250509A1 (en) 2009-11-26
CO6280501A2 (es) 2011-05-20

Similar Documents

Publication Publication Date Title
US7807854B2 (en) Effective use method of medicaments and method of preventing expression of side effect
KR101848121B1 (ko) 통풍 발열의 치료법
US20080153882A1 (en) Pharmaceutical Composition Comprising Ppar Regulator
US7851443B2 (en) Combination comprising combretastatin and anticancer agents
US20080255181A1 (en) Methods for treating podocyte-related disorders
CA3044059A1 (fr) Methodes de traitement de glycogenose
US6426366B1 (en) Pharmaceutical compositions comprising tyrphostins
US7862812B2 (en) Methods for decreasing immune response and treating immune conditions
EP2305305A1 (fr) Agent d'induction/d'entretien de rémission
US9987301B2 (en) Heparin-based compositions and methods for the inhibition of metastasis
US10507228B2 (en) Methods and compositions related to KRAS inhibitors
US20210308106A1 (en) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
HK1155660A (en) Agent for induction/maintenance of remission
WO2025083549A1 (fr) Méthodes et combinaisons d'inhibiteurs de la voie il-23 et de modulateurs de la voie de signalisation s1p pour le traitement de maladies auto-immunes
WO2020131680A1 (fr) Composés et procédés de traitement de polykystose rénale (pkd)
JPWO2020090967A1 (ja) 線維化誘導遺伝子の発現抑制剤およびその用途
US20160128994A1 (en) Ppar gamma modulators for treating cystic diseases
HK1214758A1 (en) S1p receptor modulators for treating multiple sclerosis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150520